CureVac BV raised US$213 million in its initial public offering on Thursday, a person familiar with the matter said, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the novel coronavirus.
For the foreseeable future, the market is facing a shortage of capacity – hardly the conditions that spell imminent disaster, says Richard Waters for...